Letter: New Thresholds Need to Be Defined When Using Point of Care Assays to Monitor Infliximab Trough Levels in IBD Patients

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.14645
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy